[#item_full_content] The Biden administration is reportedly considering moving marijuana from Schedule 1—the same category as heroin—to Schedule 3, which includes drugs like ketamine and some prescription medications. While the change would not legalize cannabis nationwide, it would ease federal restrictions, open the door for medical research, and lift tax burdens that have weighed down legal cannabis businesses. Supporters see this as a long-overdue shift, while critics argue the timing is politically risky. The decision, expected in the coming weeks, could reshape the cannabis industry and U.S. drug policy. 
Read More
